Drugs / MDCO-157
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01860105 Comparator | Sep 2012 → Jan 2013 | — | The Medicines Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDCO-157 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01860105 ↗ |
| Known as | clopidogrel | “MDCO-157, an intravenous formulation of clopidogrel complexed with sulphobutylether betacyclodextrin” PMID 26386578 ↗ Feb 2016 |
| Action | Inhibit | “dose-response of MDCO-157 for platelet aggregation inhibition and P2Y12 receptor inhibition effects” NCT01860105 ↗ |
| Route | Intravenous | “intravenous administration” NCT01860105 ↗ |